Initial Results of Ibrutinib Plus Venetoclax in Relapsed Refractory CLL - 100459

Spotlight
Video

Initial Results of Ibrutinib Plus Venetoclax in Relapsed Refractory CLL

moasc has 313 videos Subscribe Here

Loading........
Description: Ann Eapen, MD, from UC-Irvine Department of Hematology and Oncology is presenting the CLARITY Trial (Bloodwise TAP Study) which looks at the high rates of overall response, complete remission, and MRD eradication after 6 months of combination therapy at the MOASC’s "Spotlight On: Hematology" in Huntington Beach.
Shared By : moasc
Posted on : 02/01/18
Added : 7 months ago